- Early results from an experimental coronavirus vaccine show no major safety problems and suggest that it spurs the desired immune system responses, researchers reported in the New England Journal of Medicine.
- The US government has awarded Novavax, a company based in Gaithersburg, Maryland, USD 1.6 billion to help develop and make the vaccine, which is given as two shots, three weeks apart.
- It includes a protein from the coronavirus to prompt the immune system to make antibodies to fight infection.
- The study tested two dose levels in 108 healthy people and compared responses to 23 others who got placebo shots.
- Most of those given vaccine also received an adjuvant — a substance often included in vaccines to boost the immune system’s response and stretch a limited supply.
- The adjuvant seemed safe; those who got it with the lower dose made antibodies in far greater numbers than what’s typically seen in people recovering from natural infection with COVID-19.
Categories
- 2025
- Business
- Compilations
- Daily Current Affairs
- Design / Branding
- Downloads
- Economic survey and budget
- editorial
- Essay Writing Practice
- Free Content For Members
- imp
- Interview
- IR
- Magazine
- Mains Solution
- misc
- Monthly Current-Affairs Pointers
- Monthly Mains Answer Writing Practise Questions
- Prelims-CSAT
- Prelims-GS
- Previous Year Question Papers
- R&I
- Resource List For UPSC
- Syllabus
- Test
- Uncategorized
- upsc
Archives
You May Also Like
Current affairs 5th September 2025 By Right IAS Topic – Cochlear implant56th GST Council Meeting  A cochlear implant is a...
-
-
September 5, 2025
Current affairs 27th August 2025 By Right IAS Guidelines for regulating speech on social mediaSupreme Court’s Intervention: The Supreme Court...
-
-
August 27, 2025
Current affairs 26th August 2025 By Right IAS Fossil Discoveries in India Western India’s open coal mines contain some of...
-
-
August 26, 2025
No courses found!